The decision by Fass to rape the treasury immediately rather than on a deferred basis may have triggered a series of "disgust" sales. That is just a thesis, probably a bad one at that.
As for hitting 2--boy, that would be enticing. I have to wonder what turned Teva off. . .
At one one point I could have sold for 18--makes me wonder why I have held on. Fortunately my position is small.
Clement has his hands full. I have this weird feeling that we are approaching a point at which Rosemont by itself becomes a more appetizing morsel, particularly to a European firm. But that is just one guy's outlook.
All the best and keep up the poetry. By the way, look at BPA on the Amex. Management is just the opposite of Fass--has made bundles growning and selling off several pharma.